It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD) . Shares have added about 0.6% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Acadia Q1 Earnings Surpass Estimates, ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences:Citizens JMP Life Sciences ConferenceFireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY2024 RBC Capital Markets Global Healthcare ConferenceFireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NYBofA Securities Health Care ConferenceFireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Eastern Time in Las V ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY 2024 RBC Capital Markets Global Healthcare Conference Fireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NY BofA Securities Health Care Conference Fireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Eastern Time in ...

Acadia Pharmaceuticals Inc. (ACAD) reported first-quarter 2024 earnings of 10 cents per share, beating the Zacks Consensus Estimate of 4 cents. In the year-ago quarter, the company had incurred a loss of 27 cents per share.The bottom line improved year over year owing to higher product sales.Acadia recorded total revenues of $205.8 million, which missed the Zacks Consensus Estimate of $206.9 million. Acadia’s net product revenues comprise revenues generated from the sale of its two marketed products, Nuplaz ...

财务数据和关键指标变化 - 第一季度总收入为2.058亿美元,同比增长74% [12] - NUPLAZID第一季度销售额为1.299亿美元,同比增长10% [57] - DAYBUE第一季度销售额为7590万美元,这是公司首次完成这个日历季度的销售 [12] - 公司现金余额为4.705亿美元,较2023年年末增加了3160万美元 [77] 各条业务线数据和关键指标变化 - DAYBUE销售额同比季度下降13%,主要由于销量下降10%和毛利率下降3% [72] - NUPLAZID销售额同比增长10%,主要由于新患者开始量增加 [57][175][177] 各个市场数据和关键指标变化 - 帕金森病精神病市场整体保持平稳,NUPLAZID在社区和长期护理渠道的表现优于市场 [57][175][177] 公司战略和发展方向及行业竞争 - 公司有两个商业化产品DAYBUE和NUPLAZID,同时还有多个后期临床项目 [11][25][28] - DAYBUE在美国市场渗透率已达25%,未来有很大的增长空间 [16][31][48] - 公司正在推进DAYBUE在其他市场的上市,包括欧洲和加拿大 [50][51] - 公司正在开发治疗普拉德-威利综合征和阿尔茨海默病精神病的新药 [26][27][66] 管理层对经营环境和未来前景的评论 - 公司有强大的商业化能力和财务实力,为未来发展奠定了基础 [11][14] - DAYBUE的长期价值驱动因素包括持续提高市场渗透率和优于临床试验的持续性 [16][39][45] - NUPLAZID仍是一个强劲的现金流产生业务 [12][25] - 公司有丰富的临床管线,为未来发展提供了多个机会 [25][28][60] 问答环节重要的提问和回答 问题1 **Tessa Romero 提问** 询问公司在业务发展方面的策略和资本配置 [86][87][92] **Steve Davis 回答** 公司在业务发展方面保持开放态度,会根据具体机会选择早期或后期资产 [88][89][93] 问题2 **Ritu Baral 提问** 询问DAYBUE患者群体中的多样性情况,以及停药和重新开始用药的情况 [97][100][103] **Brendan Teehan 回答** 公司密切关注患者群体的多样性情况,并提供支持以帮助患者持续用药 [99][101][102][103] 问题3 **Ash Verma 提问** 询问公司是否考虑调整成本结构 [151][154][155][156] **Mark Schneyer 回答** 公司会持续审视成本结构,根据业务发展需要进行适当调整 [154][155][156]

First Quarter 2024 Earnings Call May 8, 2024 Call Agenda Welcome Al Kildani | Senior Vice President, Investor Relations and Corporate Communications CEO Opening Remarks Steve Davis | President and Chief Executive Officer Comme ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 06-1376651 (State of Incorporation) (I.R.S. Employer Identification No.) 1 ...

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 150%. A quarter ago, it was expected that this drugmaker would post earnings of $0.32 per share when it actually produced earnings of $0.28, delivering a surprise of -12.50%.Over the last four quarters, the comp ...

Exhibit 99.1 Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview - First quarter NUPLAZID® (pimavanserin) net product sales of $129.9 million - First quarter DAYBUE™ (trofinetide) net product sales of $75.9 million SAN DIEGO, CA, May 8, 2024 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2024. “In the first quarter of 2024, Acadia delivered net product sales of $205.8 million, representing 74% re ...

The earnings season for the drug/biotech sector is now in its final lap, with two S&P 500 companies, Viatris (VTRS) and Perrigo Company (PRGO) , and some other drug/generic companies due to report their first-quarter 2024 results this week.The majority of the large drugmakers have already reported their results. Many of these companies beat estimates for both earnings and sales. Some companies also raised their guidance for 2024, mainly the earnings per share outlook.Per the Zacks classification, the pharma ...